IsC-F2KU2, IsC41-F2KU2#17
CIRAi006-A-1
General
Cell Line |
|
| hPSCreg name | CIRAi006-A-1 |
| Cite as: | CIRAi006-A-1 (RRID:CVCL_ZA44) |
| Alternative name(s) |
IsC-F2KU2, IsC41-F2KU2#17
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 29th May 2020 |
| Notes | FSHD2 patient-derived iPSC with SMCHD1 mutation corrected and without transgenes |
| User feedback | |
Provider |
|
| Generator | Center for iPS Cell Research and Application (CIRA) |
| Owner | Center for iPS Cell Research and Application (CIRA) |
| Distributors | |
| Derivation country | Japan |
External Databases |
|
| BioSamples | SAMEA7001540 |
| Cellosaurus | CVCL_ZA44 |
| Wikidata | Q98125630 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Japanese |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7001539 |
Ethics
Also have a look at the ethics information for the parental line
CIRAi006-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CIRAi006-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemFit® AK02N
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| FOXA2 |
Yes |
| SOX17 |
Yes |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.